Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

11,981 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Metastatic melanoma.
Sun W, Schuchter LM. Sun W, et al. Curr Treat Options Oncol. 2001 Jun;2(3):193-202. doi: 10.1007/s11864-001-0033-5. Curr Treat Options Oncol. 2001. PMID: 12057119 Review.
Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice.
Goel G, Sun W. Goel G, et al. Among authors: sun w. J Hematol Oncol. 2015 Jul 28;8:92. doi: 10.1186/s13045-015-0183-8. J Hematol Oncol. 2015. PMID: 26215324 Free PMC article.
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
Safran H, Miner T, Bahary N, Whiting S, Lopez CD, Sun W, Charpentier K, Shipley J, Anderson E, McNulty B, Schumacher A, Clark A, Vakharia J, Kennedy T, Sio T. Safran H, et al. Among authors: sun w. Am J Clin Oncol. 2011 Feb;34(1):50-2. doi: 10.1097/coc.0b013e3181d26b01. Am J Clin Oncol. 2011. PMID: 24757739 Clinical Trial.
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ. Beatty GL, et al. Among authors: sun w. Clin Cancer Res. 2013 Nov 15;19(22):6286-95. doi: 10.1158/1078-0432.CCR-13-1320. Epub 2013 Aug 27. Clin Cancer Res. 2013. PMID: 23983255 Free PMC article. Clinical Trial.
A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
Sun W, Hewitt MR, Theobald MR, Hershock D, Haller DG. Sun W, et al. Cancer. 2007 Dec 15;110(12):2768-74. doi: 10.1002/cncr.23098. Cancer. 2007. PMID: 17932893 Clinical Trial.
Cancers of the large bowel and hepatobiliary tract.
Sun W, Haller D. Sun W, et al. Cancer Chemother Biol Response Modif. 2003;21:509-34. doi: 10.1016/s0921-4410(03)21024-3. Cancer Chemother Biol Response Modif. 2003. PMID: 15338761 Review. No abstract available.
Developments in treatment of esophageal/gastric cancer.
Liu W, Zhang X, Sun W. Liu W, et al. Among authors: sun w. Curr Treat Options Oncol. 2008 Dec;9(4-6):375-87. doi: 10.1007/s11864-009-0097-1. Epub 2009 Apr 26. Curr Treat Options Oncol. 2008. PMID: 19396633 Review.
What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy?
Sohal DP, Sun W. Sohal DP, et al. Among authors: sun w. Expert Rev Anticancer Ther. 2011 Dec;11(12):1843-50. doi: 10.1586/era.11.170. Expert Rev Anticancer Ther. 2011. PMID: 22117152
Hepatocellular carcinoma: prevention and therapy.
Sohal DP, Sun W. Sohal DP, et al. Among authors: sun w. Curr Oncol Rep. 2011 Jun;13(3):186-94. doi: 10.1007/s11912-011-0165-0. Curr Oncol Rep. 2011. PMID: 21409527
Systemic and targeted therapy for advanced colon cancer.
Hegde SR, Sun W, Lynch JP. Hegde SR, et al. Among authors: sun w. Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):135-49. doi: 10.1586/17474124.2.1.135. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072376 Review.
11,981 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback